HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Commissioner McClellan? HHS’ Thompson Says Nomination Is Imminent

This article was originally published in The Rose Sheet

Executive Summary

The Bush Administration appears ready to move forward with the nomination of health advisor Mark McClellan, MD/PhD, as FDA commissioner

You may also be interested in...



FDA Commissioner Nominee McClellan Appears To Be On Fast Track In Senate

The Senate Health Committee appears to be fast-tracking the confirmation process for FDA commissioner nominee Mark McClellan, MD/PhD

FDA Commissioner Nominee McClellan Appears To Be On Fast Track In Senate

The Senate Health Committee appears to be fast-tracking the confirmation process for FDA commissioner nominee Mark McClellan, MD/PhD

FDA Commish Pick OK With Kennedy, Thompson Says; Bush Nod Awaited

Virginia Tech Center for Food & Nutrition Policy Director Lester Crawford, DVM/PhD, may represent the Bush administration's last chance to nominate an FDA commissioner this year.

Latest Headlines
See All
UsernamePublicRestriction

Register

RS010613

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel